174 related articles for article (PubMed ID: 23806812)
1. Development of intravenous lipid emulsion of vinorelbine based on drug-phospholipid complex technique.
Li Y; Jin W; Yan H; Liu H; Wang C
Int J Pharm; 2013 Sep; 454(1):472-7. PubMed ID: 23806812
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy, toxicity and safety of vinorelbine incorporated in a lipid emulsion.
Su M; Zhao M; Luo Y; Lin X; Xu L; He H; Xu H; Tang X
Int J Pharm; 2011 Jun; 411(1-2):188-96. PubMed ID: 21421039
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
Webb MS; Johnstone S; Morris TJ; Kennedy A; Gallagher R; Harasym N; Harasym T; Shew CR; Tardi P; Dragowska WH; Mayer LD; Bally MB
Eur J Pharm Biopharm; 2007 Mar; 65(3):289-99. PubMed ID: 17123800
[TBL] [Abstract][Full Text] [Related]
4. A lyophilized etoposide submicron emulsion with a high drug loading for intravenous injection: preparation, evaluation, and pharmacokinetics in rats.
Chen H; Shi S; Zhao M; Zhang L; He H; Tang X
Drug Dev Ind Pharm; 2010 Dec; 36(12):1444-53. PubMed ID: 21050136
[TBL] [Abstract][Full Text] [Related]
5. Development of plumbagin-loaded phospholipid-Tween® 80 mixed micelles: formulation, optimization, effect on breast cancer cells and human blood/serum compatibility testing.
Bothiraja C; Kapare HS; Pawar AP; Shaikh KS
Ther Deliv; 2013 Oct; 4(10):1247-59. PubMed ID: 24116910
[TBL] [Abstract][Full Text] [Related]
6. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes.
Liu Y; Lu WL; Guo J; Du J; Li T; Wu JW; Wang GL; Wang JC; Zhang X; Zhang Q
J Control Release; 2008 Jul; 129(1):18-25. PubMed ID: 18466993
[TBL] [Abstract][Full Text] [Related]
7. Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology.
Li CL; Cui JX; Wang CX; Zhang L; Li YH; Zhang L; Xiu X; Li YF; Wei N
Int J Pharm; 2010 May; 391(1-2):230-6. PubMed ID: 20214962
[TBL] [Abstract][Full Text] [Related]
8. A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics.
Zhang HY; Tang X; Li HY; Liu XL
Int J Pharm; 2008 Feb; 348(1-2):70-9. PubMed ID: 17719191
[TBL] [Abstract][Full Text] [Related]
9. [Characterization of vinflunine tartrate liposomes in vitro and in vivo].
Zou WW; Wang DH; Sun CY; Han JB; Yin Q; Yang QM; Wang JY
Yao Xue Xue Bao; 2011 Dec; 46(12):1515-9. PubMed ID: 22375428
[TBL] [Abstract][Full Text] [Related]
10. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies.
Wang S; Chen T; Chen R; Hu Y; Chen M; Wang Y
Int J Pharm; 2012 Jul; 430(1-2):238-46. PubMed ID: 22465546
[TBL] [Abstract][Full Text] [Related]
11. Development of intravenous lipid emulsion of tanshinone IIA and evaluation of its anti-hepatoma activity in vitro.
Chu T; Zhang Q; Li H; Ma WC; Zhang N; Jin H; Mao SJ
Int J Pharm; 2012 Mar; 424(1-2):76-88. PubMed ID: 22226873
[TBL] [Abstract][Full Text] [Related]
12. Development and characteristics of temperature-sensitive liposomes for vinorelbine bitartrate.
Zhang H; Wang ZY; Gong W; Li ZP; Mei XG; Lv WL
Int J Pharm; 2011 Jul; 414(1-2):56-62. PubMed ID: 21596128
[TBL] [Abstract][Full Text] [Related]
13. Lyophilized Cheliensisin A submicron emulsion for intravenous injection: characterization, in vitro and in vivo antitumor effect.
Zhao D; Gong T; Fu Y; Nie Y; He LL; Liu J; Zhang ZR
Int J Pharm; 2008 Jun; 357(1-2):139-47. PubMed ID: 18329194
[TBL] [Abstract][Full Text] [Related]
14. Vinorelbine (Navelbine): a third-generation vinca alkaloid.
Budman DR
Cancer Invest; 1997; 15(5):475-90. PubMed ID: 9316630
[TBL] [Abstract][Full Text] [Related]
15. Phospholipid-Tween 80 mixed micelles as an intravenous delivery carrier for paclitaxel.
Liang H; Yang Q; Deng L; Lu J; Chen J
Drug Dev Ind Pharm; 2011 May; 37(5):597-605. PubMed ID: 21469948
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.
Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Saijo N; Nishiwaki Y
Lung Cancer; 2007 Mar; 55(3):337-41. PubMed ID: 17126951
[TBL] [Abstract][Full Text] [Related]
17. A stable and practical etoposide-containing intravenous long-/medium-chain triglycerides-based lipid emulsion formulation: pharmacokinetics, biodistribution, toxicity, and antitumor efficacy.
Dong W; Zhang L; Niu Y; Fan D; Wu X; Tang X; Cai C
Expert Opin Drug Deliv; 2013 May; 10(5):559-71. PubMed ID: 23373755
[TBL] [Abstract][Full Text] [Related]
18. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity.
Semple SC; Leone R; Wang J; Leng EC; Klimuk SK; Eisenhardt ML; Yuan ZN; Edwards K; Maurer N; Hope MJ; Cullis PR; Ahkong QF
J Pharm Sci; 2005 May; 94(5):1024-38. PubMed ID: 15793796
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid.
Brogden JM; Nevidjon B
Oncol Nurs Forum; 1995 May; 22(4):635-46. PubMed ID: 7675666
[TBL] [Abstract][Full Text] [Related]
20. Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice.
Filipski E; Amat S; Lemaigre G; Vincenti M; Breillout F; Lévi FA
J Pharmacol Exp Ther; 1999 Apr; 289(1):231-5. PubMed ID: 10087009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
